|
17 May 2025 |
Divi's Laboratories
|
Consensus Share Price Target
|
6279.50 |
5952.83 |
- |
-5.20 |
hold
|
|
|
|
|
08 Nov 2022
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
6279.50
|
3300.00
|
3298.75
(90.36%)
|
Target met |
Hold
|
|
|
|
|
08 Nov 2022
|
Divi's Laboratories
|
ICICI Securities Limited
|
6279.50
|
3893.00
|
3414.55
(83.90%)
|
Target met |
Accumulate
|
|
|
Divi’s Laboratories’ (Divi’s) Q2FY23 performance was sharply below our estimates. Consolidated revenue fell 6.7% YoY to Rs18.5bn (I-Sec: Rs22.9bn), EBITDA margin slipped 770bps YoY to 33.5% (I-Sec: 41.2%) and adjusted PAT declined 18.6% YoY to Rs4.9bn (I-Sec: Rs6.2bn).
|
|
08 Nov 2022
|
Divi's Laboratories
|
ICICI Direct
|
6279.50
|
3685.00
|
3414.55
(83.90%)
|
Target met |
Hold
|
|
|
|
|
03 Oct 2022
|
Divi's Laboratories
|
Ashika Research
|
6279.50
|
4110.00
|
3726.85
(68.49%)
|
|
Buy
|
|
|
|
|
25 Aug 2022
|
Divi's Laboratories
|
Geojit BNP Paribas
|
6279.50
|
4006.00
|
3587.50
(75.04%)
|
|
Buy
|
|
|
|
|
16 Aug 2022
|
Divi's Laboratories
|
ICICI Securities Limited
|
6279.50
|
4173.00
|
3726.20
(68.52%)
|
|
Accumulate
|
|
|
Divi’s Laboratories’ (Divi’s) Q1FY23 performance was a mixed bag with revenue ahead of our estimates while margin was lower.
|
|
15 Aug 2022
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
6279.50
|
4140.00
|
3732.00
(68.26%)
|
|
Accumulate
|
|
|
|
|
13 Aug 2022
|
Divi's Laboratories
|
BOB Capital Markets Ltd.
|
6279.50
|
4250.00
|
3726.20
(68.52%)
|
|
Hold
|
|
|
Q1 revenue broadly in line with consensus at Rs 22.5bn (+15% YoY/-10% QoQ), but EBITDA 10% below
|
|
12 Aug 2022
|
Divi's Laboratories
|
ICICI Direct
|
6279.50
|
4315.00
|
3726.20
(68.52%)
|
|
Buy
|
|
|
|
|
26 May 2022
|
Divi's Laboratories
|
SMC online
|
6279.50
|
|
3514.70
(78.66%)
|
|
Results Update
|
|
|
|